Health Trials

Refractory Large B Cell Lymphoma

3

Review clinical trials related to Refractory Large B Cell Lymphoma. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Study of Efficacy and Safety of CRC01 in Adult Large B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia Patients

This is a multi-center, phase I/II study to determine the efficacy and safety of CRC01 in adult patients with relapsed or refractory large B-cell lymphoma and B-cell Acute Lymphoblastic Leukemia.

Participants needed: 91
Trial details
Phase: Phase 1, Phase 2Age: 19+Biological sex: AllType: InterventionalSponsor: Curocell Inc.Updated: Jul 1, 2026Locations: 2
Eligibility criteria

≥ 19 years of age and provided written informed consent [+24]

Patients with the following medical history [+72]

Read more
Status: Recruiting

Study of Safety and Efficacy of TC011 in the Relapsed/Refractory Large B Cell Non-Hodgkin Lymphoma Patients

This is a multi-center, phase I/II study to determine the safety and efficacy of TC011(CD19 Targeted CAR-T) in adult patients with relapsed or refractory large B-cell non -hodgkin lymphoma.

Participants needed: 98
Trial details
Phase: Phase 1, Phase 2Age: 19+Biological sex: AllType: InterventionalSponsor: TICAROS Co., Ltd.Updated: Mar 16, 2026Locations: 1
Eligibility criteria

≥19 years old, ECOG 0-2, life expectancy ≥12 weeks [+7]

Unresolved ≥Grade 2 toxicities from prior therapy [+12]

Read more
Status: Recruiting

Outpatient Epcoritamab as 2L in NTE R/R DLBCL

The purpose of this study is to measure the efficacy of the study drug, epcoritamab, in participants with relapsed/refractory large B-cell lymphoma.

Participants needed: 30
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Massachusetts General HospitalUpdated: Feb 24, 2026Locations: 2
Eligibility criteria

Diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS) [+31]

Participant must not have used an investigational drug or approved systemic lymp... [+20]

Read more